Answers are grounded in this paper and cite their sources.
To the Editors, Inflammatory bowel disease, pyoderma gangrenosum (PG), and alopecia areata (AA) are autoimmune/immune-mediated disorders characterized by chronic inflammation of the gastrointestinal tract, neutrophil dysfunction with abnormal response to injury (pathergy), and T cell–mediated hair loss, respectively. Tofacitinib, a pan-janus kinase (JAK) inhibitor, is approved for the treatment of ulcerative colitis (UC),1 with case reports showing successful off-label use in AA2 and in patients with PG with prior failure to tumor necrosis factor (TNF) antagonists.3 We present a case of a female patient with UC, AA, and post-surgical PG resistant to treatment with topical tacrolimus and systemic treatment with TNF-antagonists, who had improvement in all three conditions after treatment with tofacitinib. An 80-year-old female with distal UC diagnosed in 2007 was treated successfully with oral aminosalicylates. In 2017, after a right hip replacement, she developed aggressive de novo pyoderma gangrenosum at the postoperative site, which...
No takes yet. Share an insight, caveat, or question.
Sedaño et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: